Progyny reported second quarter 2026 revenue of $350.5 million, a 5.3% increase year-over-year and an 11.0% increase excluding the impact of a large former client. Net income rose to $28.1 million ($0.34 per diluted share) from $17.1 million in the prior year period, driven by gross margin expansion to 25.5% and lower stock-based compensation expense. Adjusted EBITDA reached $62.1 million with a 17.7% margin. The company repurchased nearly 1.2 million shares for $31.5 million during the quarter, bringing cumulative repurchases under the current authorization to approximately 2 million shares with $142.5 million remaining authorized. Progyny provided full-year 2026 revenue guidance of $1.36 billion to $1.385 billion and third-quarter revenue guidance of $335 million to $345 million. The company operates in the women's health and family building solutions industry, providing fertility benefits and related healthcare services.